During the past decade, University of South Florida/Tampa General Hospital conducted 21 clinical trials. In the 10-year time frame, 21 clinical trials started and 9 clinical trials were completed, i.e. on average, 42.9% percent of trials that started reached the finish line to date. In the past 5 years, 15 clinical trials started and 7 clinical trials were completed. i.e. 46.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "University of South Florida/Tampa General Hospital" #1 sponsor was "University of South Florida" with 5 trials, followed by "Canyon Pharmaceuticals, Inc." with 2 trials sponsored, "NewLink Genetics Corporation" with 2 trials sponsored, "United Therapeutics" with 2 trials sponsored and "Arteriocyte, Inc." with 2 trials sponsored. Other sponsors include 24 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "University of South Florida/Tampa General Hospital" #1 collaborator was "National Institute of Neurological Disorders and Stroke (NINDS)" with 2 trials as a collaborator, "Beijing Tiantan Hospital" with 1 trials as a collaborator, "Biomedical Advanced Research and Development Authority" with 1 trials as a collaborator, "Biotec Services International Ltd" with 1 trials as a collaborator and "CBR International Corp." with 1 trials as a collaborator. Other collaborators include 12 different institutions and companies that were collaborators in the rest 22 trials.

According to Clinical.Site data, the most researched conditions in "University of South Florida/Tampa General Hospital" are "Pancreatic Cancer" (3 trials), "Burns" (2 trials), "COVID-19" (2 trials), "Abdominal Aortic Aneurysm" (1 trials) and "Abscess" (1 trials). Many other conditions were trialed in "University of South Florida/Tampa General Hospital" in a lesser frequency.

Most popular intervention types in "University of South Florida/Tampa General Hospital" are "Drug" (15 trials), "Device" (13 trials), "Other" (9 trials), "Biological" (7 trials) and "Procedure" (5 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Gemcitabine" (2 trials), "Oral treprostinil" (2 trials), "Symptom questionnaire" (2 trials) and "3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass" (1 trials). Other intervention names were less common.

The vast majority of trials in "University of South Florida/Tampa General Hospital" are 39 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "University of South Florida/Tampa General Hospital". 1 are not yet recruiting, 11 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 13 completed trials in University of South Florida/Tampa General Hospital, undefined suspended trials, and 10 terminated clinical trials to date.

Out of the total trials that were conducted in University of South Florida/Tampa General Hospital, 4 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 11 trials that are defined as “Not Applicable".